UPI (MM)

MINNEAPOLIS, Sept. 21 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Nasdaq: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that David Kaysen, Uroplasty's President and CEO, and Medi Jiwani, Uroplasty's Vice President and CFO, will present the Company's business strategy and financial results at The Fifth Annual JMP Securities Healthcare Conference at 12:00 PM ET on Tuesday, September 28, 2010 at The New York Palace Hotel in New York.

Attendance at the conference is by invitation only.  A live audio webcast of the presentation will be broadcast via the Internet.  Those interested in listening to the webcast may access it at http://www.wsw.com/webcast/jmp11/upi/, or through Uroplasty's website at www.uroplasty.com. An archived replay of the presentation will be available for 90 days.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent PC system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence – symptoms often associated with overactive bladder.

We also offer Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

SOURCE Uroplasty, Inc.